Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17027567 | 0.86 | GABRA1 (0.36) | MAPK1TDP1NMT1GABRA1GABRB2 | |
| SCHEMBL29648901 | 0.86 | GABRA1 (0.36) | MAPK1TDP1NMT1GABRA1GABRB2 | |
| SCHEMBL10614885 | 0.83 | GABRA1 (0.50) | MAPK1TDP1NMT1GABRA1GABRB2 | |
| SCHEMBL11322087 | 0.82 | GABRA1 (0.42) | MAPK1TDP1GABRA1GABRB2 | |
| SCHEMBL1019709 | 0.81 | MAPK1 (0.45) | MAPK1TDP1GABRA1GABRB2 | |
| SCHEMBL5206535 | 0.79 | MAPK1 (0.59) | MAPK1TDP1GABRA1GABRB2 | |
| SCHEMBL1950823 | 0.77 | MAPK1 (0.42) | MAPK1TDP1GABRA1GABRB2 | |
| SCHEMBL9834243 | 0.77 | MAPK1 (0.38) | MAPK1TDP1GABRA1GABRB2 | |
| SCHEMBL8641955 | 0.76 | MAPK1 (0.50) | MAPK1TDP1GABRA1GABRB2 | |
| SCHEMBL2728021 | 0.76 | TDP1 (0.36) | MAPK1TDP1GABRA1GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO. LTD. (JP) | 2005-04-21 | — | — | US | disclosed |
| CN-1578767-A | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO (JP) | 2005-02-09 | — | — | CN | disclosed |
| EP-1447401-A1 | PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085509-A1 | Piperidin-2-one derivative compounds and drugs containing these compounds as the active ingredient | MAPKAP1, MAPK1, MAPK8 | MAPK1 2/4885TDP1 1960/4885NMT1 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.